Why the TRANSCEND data and new approvals matter for Rhythm Pharmaceuticals stock

Rhythm Pharmaceuticals (RYTM) is in focus after pivotal Phase 3 TRANSCEND trial results for setmelanotide in acquired hypothalamic obesity were published in The New England Journal of Medicine, alongside recent US and European regulatory milestones.

Rhythm Pharmaceuticals’ share price has climbed strongly in recent months, with a 30 day share price return of 33.17% and a 90 day gain of 32.86%, while the 1 year total shareholder return of 28.57% sits alongside a very large 3 year total shareholder return that reflects how much sentiment around its rare disease portfolio has shifted as TRANSCEND data and fresh approvals have come through.

If Rhythm’s recent run in rare disease treatments has your attention, this could be a good moment to widen your search and check out 40 healthcare AI stocks

After such a sharp move on the back of TRANSCEND and new approvals, Rhythm Pharmaceuticals now sits at a market value of about US$7.8b. The real puzzle is whether most of the re rating is already behind the stock or still ahead of it.

Most Popular Narrative: 18% Undervalued

The most followed Rhythm Pharmaceuticals narrative sees a fair value of about $139.47 per share versus the last close at $114.43, framing the TRANSCEND momentum inside a much bigger rare disease growth story that runs through 2029 and beyond.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years. Extension of intellectual property protection to 2034 for the lead asset and to 2040+ for next generation compounds, along with orphan drug exclusivity incentives in the U.S. and EU, create a multi year window of strong pricing power and high net margins, protecting earnings from generic or biosimilar erosion.

Want to see what kind of revenue curve and profit profile sit behind that outlook for Rhythm Pharmaceuticals? The narrative leans on aggressive top line expansion, a sharp swing from losses to sizeable earnings, and a premium future earnings multiple that many investors normally associate with higher growth sectors. Curious which specific profit assumptions and valuation hurdles need to be met to justify that fair value gap and the analyst target path behind it?

Result: Fair Value of $139.47 (UNDERVALUED)

However, Rhythm Pharmaceuticals still carries key risks, including ongoing operating losses and heavy reliance on setmelanotide, which could challenge the bullish growth narrative.

Another view on Rhythm Pharmaceuticals valuation

The fair value work around Rhythm Pharmaceuticals so far leans on long term cash flows and analyst forecasts, but current trading tells a different story. At a P/S of 36.1x versus 12.2x for the US Biotechs industry and 10x for peers, the stock carries a heavy premium. With a fair ratio of 20.1x, that gap could either shrink or the business might need to keep justifying a richer multiple. Which side do you think gives first?

See what the numbers say about this price, find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment around Rhythm Pharmaceuticals leaning optimistic, this is a good time to review the data yourself, pressure test the narratives, and weigh both upside and risk using the 3 key rewards

Looking for more investment ideas beyond Rhythm Pharmaceuticals?

If Rhythm Pharmaceuticals has sharpened your focus on where capital works hardest, do not stop here. Broaden your watchlist now and keep fresh ideas on your radar.

• Target potential mispricings by scanning companies that combine quality with attractive valuations using the 44 high quality undervalued stocks
• Strengthen your income stream by hunting for stocks built around robust, higher yielding payouts via the 9 dividend fortresses
• Prioritise resilience by reviewing companies with sturdier balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (47 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.